GlassScriptPhysician profile
Shane Paul Dormady
NPI 1417024654
$3,144.49
in general payments reported to CMS, 2019-2025
25 companies · $1,395 in 2025
The $1,395 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,224 · 2020: $293 · 2021: $11.92 · 2022: $34.08 · 2023: $40.92 · 2024: $145 · 2025: $1,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,000 · Food and Beverage: $525 · Education: $55.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,000.00 |
| Food and Beverage | $525.35 |
| Education | $55.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caris Mpi, INC. | $1,232.74 | 2025 | Mi Cancer Seek |
| Lilly USA, LLC | $213.17 | 2019-2023 | Jaypirca, Verzenio |
| Novartis Pharmaceuticals Corporation | $192.88 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $180.00 | 2019-2025 | Lynparza |
| Merck Sharp & Dohme LLC | $163.08 | 2019-2020 | |
| Adc Therapeutics America, INC. | $144.64 | 2024 | |
| Pfizer INC. | $125.86 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $107.65 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $107.05 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $95.45 | 2019-2020 | |
| Incyte Corporation | $75.78 | 2019-2020 | |
| Seagen INC. | $66.60 | 2019-2020 | |
| Celgene Corporation | $65.54 | 2019-2020 | |
| Janssen Biotech, INC. | $53.53 | 2019 | |
| Amgen INC. | $52.59 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $50.91 | 2019 | |
| Emd Serono, INC. | $45.83 | 2019 | |
| Foundation Medicine, INC. | $28.61 | 2019-2020 | |
| Eisai INC. | $27.31 | 2020 | |
| Daiichi Sankyo INC. | $26.20 | 2025 | Enhertu |
| Blueprint Medicines Corporation | $24.97 | 2020 | |
| Tesaro, INC. | $22.78 | 2019 | |
| Puma Biotechnology, INC. | $17.07 | 2020 | |
| Clovis Oncology, INC. | $12.33 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Dormady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.